Mechanisms of Resistance
Mechanisms of Resistance
复制标题
DOI：
10.1007/978-3-642-65678-1_19
复制
发表时间：
1974
影响因子：
2.4
通讯作者：
E. Brockman
中科院分区：
文献类型：
--
作者：
E. Brockman
“与微生物一样，肿瘤细胞的耐药性问题仍将是治疗药物成功使用的最重要的永久威胁”（LAW，1956）。也有人说，只要癌细胞能够分裂，达尔文进化就不可避免。这些陈述的基础可以通过检查细胞群（微生物或肿瘤细胞）适应药物存在的机制来找到。生理适应，即药物引起群体变化，不涉及遗传变化，并且不是稳定的特征。遗传适应，即在药物存在的情况下选择独立于药物产生的突变体，其特征是耐药性的稳定性。正如 BRYSON 和 SZYBALSKI (1955)、DEAN 和 HINSHELWOOD (1957)、PETERS (1970) 等人所指出的，这些机制并不是相互排斥的。诱变剂（在某些情况下是抗癌药物本身）可能会通过增加治疗细胞群中的突变频率来增加产生耐药性的可能性。
" The problem of resistance in neoplastic cells, as in microorganisms, will remain a most important perpetual threat to the successful use of therapeutic agents"(LAW, 1956). It also has been said, that as long as cancer cells are able to divide, Darwinian evolution is inevitable. The basis for these statements can be found by examining mechanisms by which a population of cells (microorganisms or neoplastic cells) adapt to the presence of a drug. Physiologic adaptation, in which the drug induces a change in the population, does not involve a genetic change and is not a stable characteristic. Genetic adaptation, in which mutants arising independently of the drug are selected in the presence of the drug, is characterized by stability of resistance. These mechanisms are not mutually exclusive, as pointed out by BRYSON and SZYBALSKI (1955), DEAN and HINSHELWOOD (1957), PETERS (1970), and others. Agents that are mutagenic, in some cases the anticancer drug itself, may increase the probability of the development of resistance by increasing the mutation frequency in a population of treated cells.